• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Galectin Therapeutics

edit

Galectin Therapeutics, Inc., a development stage company, engages in the discovery and development of carbohydrate-based therapeutics for the treatment of cancer, liver, microbial, and inflammatory diseases. Its lead product candidate in development, GM-CT-01, is a proprietary polysaccharide galectin inhibitor, which has completed Phase II trials for the treatment of colorectal cancer in combination with 5-FU, a chemotherapy for the treatment of various types of cancer.

The company has research collaborations with the Mount Sinai School of Medicine to study the anti-fibrotic effects of its carbohydrate compounds on liver fibrosis; with Brigham and Women’s Hospital to evaluate the anti-fibrotic effects of these compounds to treat acute and chronic kidney disease; and with the Ludwig Institute in Brussels, Belgium to show whether inhibiting the action of galectin-3 improves the efficacy of T lymphocytes in killing tumor cells.

Galectin Therapeutics (previously Pro-Pharmaceuticals) was founded in December 2000 and is based in Newton, Massachusetts.

Recent Milestones

edit

• 
  Went public with stock symbol NASDAQ:GALT. (3/23/12)
  Posted 12/10/09 at 10:49pm
• 
  Galectin Therapeutics — Galectin Therapeutics Presents Preclinical Data on the Treatment of Fatty Liver Disease and Fibrosis at EASL (12/16/11)
  Posted 12/22/11 at 4:09pm via corporate-ir.net
• 
  Galectin Therapeutics — Company launches Phase I/II trial in Europe with Ludwig Institute to Evaluate the Safety and Efficacy of Immunomodulatory Compound, GM-CT-01, with Peptide Vaccine (12/8/11)
  Posted 12/22/11 at 4:09pm via corporate-ir.net
• 
  Galectin Therapeutics — Galectin Therapeutics Announces Formation of Liver Fibrosis Clinical Trials Advisory Board (11/2/11)
  Posted 12/22/11 at 4:09pm via corporate-ir.net
• 
  Galectin Therapeutics added Marc Rubin as Board of Directors. (10/1/11)
  Posted 11/4/11 at 2:07pm
• 
  Galectin Therapeutics — 10X Fund Issues Positive Statement Regarding Investment in Galectin Therapeutics (8/5/11)
  Posted 12/22/11 at 4:09pm via corporate-ir.net
• 
  Galectin Therapeutics — Galectin Therapeutics Announces Research Collaboration with University of Michigan Medical School to Explore Role of Galectins in Cardiovascular Disease (7/21/11)
  Posted 12/22/11 at 4:09pm via corporate-ir.net
• 
  Galectin Therapeutics — Pro-Pharmaceuticals Changes Company Name to Galectin Therapeutics (5/26/11)
  Posted 9/8/11 at 5:19pm via corporate-ir.net
• 
  Galectin Therapeutics added John Mauldin as Board of Directors. (5/1/11)
  Posted 11/4/11 at 2:07pm
• 
  Galectin Therapeutics added Paul Pressler as Board of Directors. (5/1/11)
  Posted 11/4/11 at 2:07pm
• 
  Galectin Therapeutics added Kevin Freeman as Board of Directors. (5/1/11)
  Posted 11/4/11 at 2:07pm
• 
  Galectin Therapeutics — Pro-Pharmaceuticals’ DAVANAT® Targets Galectin Proteins Secreted by Cancer Cells and Eliminates The Cancer’s Ability to Evade the Immune System (4/20/11)
  Posted 12/22/11 at 4:09pm via corporate-ir.net
• 
  Galectin Therapeutics — full of optimism, saying the company has turned around. (3/16/11)
  Posted 3/17/11 at 5:02am via masshightech.com
• 
  Galectin Therapeutics — full of optimism, saying the company has turned around. (3/16/11)
  Posted 3/17/11 at 5:03am via masshightech.com
• 
  Galectin Therapeutics — named former GlaxoSmithKline and Baylor University executive Peter G. Traber as president and CEO (3/9/11)
  Posted 3/10/11 at 3:20am via masshightech.com
• 
  Galectin Therapeutics added Peter G. Traber as President and CEO, Board of Directors. (3/1/11)
  Posted 3/9/11 at 9:18pm

Videos

Screenshots

edit

Above: Home Page
Uploaded: 12/11/09

Above: Home Page
Uploaded: 9/14/11

Stock Price

Sources

1. PRO-PHARMACEUTICALS CLOSES INITIAL $1.8 MILLION TRANCHE OF UP TO $6.0 MILLION PRIVATE PLACEMENT (phx.corporate-ir.net) [edit]
2. PRO-PHARMACEUTICALS CLOSES $500,000 TRANCHE; BRINGS TOTAL TO $3.2 MILLION OF $6.0 MILLION PRIVATE PLACEMENT (this a difference tranche reported in body of article) (phx.corporate-ir.net) [edit]
3. PRO-PHARMACEUTICALS CLOSES $500,000 TRANCHE; BRINGS TOTAL TO $3.2 MILLION OF $6.0 MILLION PRIVATE PLACEMENT (phx.corporate-ir.net) [edit]
4. PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE; BRINGS TOTAL TO $3.8 MILLION OF $6.0 MILLION PRIVATE PLACEMENT (phx.corporate-ir.net) [edit]
5. PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE; BRINGS TOTAL TO $4.1 MILLION OF $6.0 MILLION PRIVATE PLACEMENT (phx.corporate-ir.net) [edit]
6. Pro-Pharmaceuticals takes another $325,000 bite of Series B (masshightech.com) [edit]
7. PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE (phx.corporate-ir.net) [edit]
8. PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE (phx.corporate-ir.net) [edit]
9. PRO-PHARMACEUTICALS RECEIVES FINAL TRANCHE OF FUNDING FROM FEDERAL GRANT; RAISES CASH POSITION TO $8 MILLION (phx.corporate-ir.net) [edit]
10. PRO-PHARMACEUTICALS CLOSES $335,000 TRANCHE (phx.corporate-ir.net) [edit]
11. PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE FROM 10X FUND (phx.corporate-ir.net) [edit]
12. PRO-PHARMACEUTICALS CLOSES FINAL $570,000 TRANCHE FROM 10X FUND TO COMPLETE $6 MILLION RAISE (phx.corporate-ir.net) [edit]
13. Pro-Pharmaceuticals pulls in $3M from stock financings (masshightech.com) [edit]
Traber named CEO at Pro-Pharmaceuticals (masshightech.com) [edit]
New Pro-Pharmaceuticals CEO Traber aims to steer company's recovery (masshightech.com) [edit]
New Pro-Pharmaceuticals CEO Traber aims to steer company's recovery (masshightech.com) [edit]
Pro-Pharmaceuticals Changes Company Name to Galectin Therapeutics (phx.corporate-ir.net) [edit]
Pro-Pharmaceuticals’ DAVANAT® Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated (phx.corporate-ir.net) [edit]
PRO-PHARMACEUTICALS & MOUNT SINAI SCHOOL OF MEDICINE ANNOUNCE NEW LIVER FIBROSIS RESEARCH COLLABORATION (phx.corporate-ir.net) [edit]
THE LUDWIG INSTITUTE AND PRO-PHARMACEUTICALS DISCOVER THAT DAVANAT® ENHANCES THE ABILITY OF ANTITUMOR T LYMPHOCYTES TO KILL TUMOR CELLS (phx.corporate-ir.net) [edit]
Galectin Therapeutics Announces Research Collaboration with Dr. Jose Jalife of the University of Michigan Medical School to Explore Role of Galectins in Cardiovascular Disease (phx.corporate-ir.net) [edit]
10X Fund Issues Statement Regarding Investment in Galectin Therapeutics (phx.corporate-ir.net) [edit]
Galectin Therapeutics Announces Formation of Liver Fibrosis Clinical Trials Advisory Board (phx.corporate-ir.net) [edit]
Novel Cancer Treatment Combination Receives Approval to Begin First-in-Human Testing for Patients with Advanced Metastatic Melanoma (phx.corporate-ir.net) [edit]
Galectin Therapeutics Presents Preclinical Data on the Treatment of Fatty Liver Disease and Fibrosis at EASL (phx.corporate-ir.net) [edit]